Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
The company said prula-cel was well tolerated, with no CRS above grade 2 and no IEC-HS or ICANS. It plans pivotal lupus nephritis trial start-up activities in Q4 2026 and expects a further data update in mid-2027.
Adicet Bio said prula-cel study data were positive for safety and efficacy in patients with systemic lupus erythematosus, with or without lupus nephritis.
The Phase 1 study of prulacabtagene leucl (prula-cel) in systemic lupus erythematosus with or without lupus nephritis showed no CRS above Grade 2, no ICANS and no IEC-HS. At 12 months, 54% of evaluable patients achieved DORIS remission and 50% achieved complete renal response.
Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced safety and efficacy data from the Phase 1 study evaluat…